The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) was established in 1997 and since its inception has obtained over 10,000 samples procured from 4,000 consented patients at OSU. The LTBSR successfully facilitates translation of basic research in leukemia to the clinical setting by making available an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The infrastructure of the OSUCCC LTBSR is supported by outstanding institutional support and is directed by Dr. Guido Marcucci, a physician-scientist and an established senior investigator in translational research in leukemia. He oversees a highly-trained staff with extensive experience in leukemia research that provides a full array of unique services to support high quality leukemia research. The LTBSR consists of a large and unique leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management are very well-developed, including the activities of tissue collection, best practices, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality. The LTBSR leverages key partnerships within .the OSUCCC and efficient coordination with other key OSUCCC Shared Resources, to provide fundamental support of a key research mission of the OSUCCC: to produce high-quality basic and clinical research in hematological malignancy. While separated with regard to the mechanisms of collecting samples and allocation of samples to investigators, the LTBSR and the OSUCCC Biorepository and Biospecimen Shared Resource for solid tumors are governed by the same operational procedures with regard to commitment to the OSUCCC research mission and patients' confidentiality. The procedures for prioritizing and distributing tissue to a large base of investigators within the OSUCCC are effectively in place. The success in managing this large leukemia tissue resource is well-supported by the broad usage of this resource by >92% OSUCCC members and by high-impact publications (e.g.. Cell, Cancer Cell, Journal Clinical Oncology, Blood) by OSUCCC investigators in which the LTBSR has played a significant role.

Public Health Relevance

The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) leverages outstanding institutional support to facilitate the translation of basic research in leukemia to the clinical setting by making available an extensive repository of blood and bone marrow samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. Services provided through the LTBSR promote best practices and provide quality control of specimens from procurement to their use in high quality cancer research discovery, while maintaining patient consent and confidentiality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-36
Application #
8555661
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-09-12
Project End
2015-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
36
Fiscal Year
2012
Total Cost
$46,435
Indirect Cost
$15,986
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819
Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294
Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322
Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874
Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814
Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :

Showing the most recent 10 out of 2211 publications